Irifrin BK eye drops 2.5%, 0.4ml No. 15

To reduce swelling of the mucous membrane of the nasopharynx, conjunctiva with colds and allergic diseases (mainly as part of combined drugs).

Conjunctival. When carrying out ophthalmoscopy, single instillations of a 2.5% solution of IrifrinЃ BK are used. As a rule, to create mydriasis, it is enough to inject 1 drop of a 2.5% solution of IrifrinЃ BK into the conjunctival sac.

The maximum mydriasis is achieved in 15-30 minutes and remains at a sufficient level for 1-3 hours. If it is necessary to maintain mydriasis for a long time, after 1 hour, repeated instillation of IrifrinЃ BK is possible.

When carrying out diagnostic procedures:

- as a provocative test in patients with a narrow profile of the anterior chamber angle and suspected angle-closure glaucoma, 1 drop of the drug is instilled once. If the difference between the values ??of intraocular pressure before instillation of IrifrinЃ BK and after dilatation of the pupil is from 3 to 5 mm Hg. Art., then the provocative test is considered positive;

- for differential diagnosis of the type of injection of the eyeball, 1 drop of the drug is instilled once; if, 5 minutes after instillation, there is a narrowing of the vessels of the eyeball, then the injection is classified as superficial, while the redness of the eye persists, the patient must be carefully examined for the presence of iridocyclitis or scleritis, because this indicates the expansion of deeper vessels.

In iridocyclitis, to prevent the development and rupture of already formed posterior synechiae and reduce exudation into the anterior chamber of the eye - 1 drop of the drug is instilled into the conjunctival sac of the diseased eye 2-3 times a day for 5-10 days, depending on the severity of the disease.

In schoolchildren with mild myopia, for the prevention of accommodation spasm during a period of high visual load - 1 drop of IrifrinЃ BK is instilled in the evening before bedtime, with progressive moderate myopia - 3 times a week in the evening before bedtime, with emmetropia - in the daytime, depending on the load ...

In case of hyperopia with a tendency to spasm of accommodation at high visual load, IrifrinЃ BK is instilled in the evening in combination with a 1% solution of cyclopentolate. Under normal visual stress, IrifrinЃ BK is instilled 3 times a week in the evening before bedtime.

When treating false and true myopia - 1 drop of IrifrinЃ BK is instilled in the evening before going to bed 2-3 times a week for a month.

Eye drops (without preservative) in the form of a clear solution from colorless to light yellow.

1 ml

phenylephrine hydrochloride 25 mg

Excipients: disodium edetate - 1 mg, sodium metabisulfite - 2 mg, citric acid - 1.16 mg, sodium citrate dihydrate - qs, hypromellose - 3 mg, water d / i - up to 1 ml.

• Hypersensitivity to the drug;

• narrow-angle or angle-closure glaucoma;

• old age in the presence of serious disorders of the cardiovascular or cerebrovascular system;

• additional dilation of the pupil during surgical operations in patients with violation of the integrity of the eyeball, as well as in violation of tear production;

• hyperthyroidism;

• hepatic porphyria;

• congenital deficiency of glucose-6-phosphate dehydrogenase;

• children under 12 years of age and patients with arterial aneurysm (10% solution);

• premature babies (2.5% solution).

With care: patients with type 2 diabetes mellitus (increased risk of increased blood pressure associated with impaired autonomic regulation); elderly patients (increased risk of reactive miosis); simultaneous use with MAO inhibitors and within 21 days after stopping their intake; due to what causes conjunctival hypoxia: patients with sickle cell anemia, wearing contact lenses, after surgery (decreased healing).

pharmachologic effect

Adrenomimetic. It has a direct stimulating effect mainly on ?-adrenergic receptors.

With systemic use, it causes narrowing of arterioles, increases OPSS and blood pressure. Cardiac output does not change or decreases, which is associated with reflex bradycardia (increased vagus tone) in response to hypertension. Phenylephrine does not raise blood pressure as sharply as norepinephrine and epinephrine, but it lasts longer. This, apparently, is due to the fact that phenylephrine is more stable and is not destroyed under the influence of COMT.

When applied topically, phenylephrine has a pronounced vasoconstrictor effect, causes mydriasis, and can lower intraocular pressure in open-angle glaucoma.

In average therapeutic doses, it practically does not affect the central nervous system.

Interaction

The mydriatic effect of phenylephrine is enhanced when used in combination with topical atropine. Due to increased vasopressor action, tachycardia may develop.

Overdose

Symptoms: overdose are anxiety, nervousness, dizziness, sweating, vomiting, heart palpitations, weak or shallow breathing.

Treatment: in the event of a systemic effect of phenylephrine, undesirable effects can be stopped by using alpha-adrenergic blocking agents, for example, from 5 to 10 mg of phentolamine intravenously. The injection can be repeated if necessary.